CRMD Stock Analysis: Buy, Sell, or Hold?
CRMD - CorMedix Inc.
$8.39
-0.21 (-2.44%)
▼
5d:
-3.12%
30d:
+5.14%
90d:
+29.88%
BUY
MODERATE Confidence
Analysis Updated: Jun 24, 2026 12:00 AM ET
Earnings: Aug 06, 2026
Smart Money Distribution
None View Scanner →
Strength: 5.4/10
Get Alerted When CRMD Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: CRMD shows positive signals but monitor for confirmation. Market pricing in 99.8% growth. Moderate conviction.
💡 BUY OPPORTUNITY: CRMD shows positive signals but monitor for confirmation. Market pricing in 99.8% growth. Moderate conviction.
In-depth Analysis How we analyze
Valuation Analysis: CRMD is currently trading at $8.39, which is considered slightly high relative to its 30-day fair value range of $8.05 to $8.74. From a valuation perspective, the stock is trading at a premium (Forward PE: 100.0) compared to its historical average (12.5). At these levels, the market is pricing in 99.8% annual earnings growth. This is a high bar to clear, indicating the stock may be priced for perfection.
Technical Outlook: Technically, CRMD is in a strong uptrend. The price is currently testing key support at $8.46. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock shows a mixed technical setup (55/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $15.20 (+76.7%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, CRMD is in a strong uptrend. The price is currently testing key support at $8.46. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock shows a mixed technical setup (55/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $15.20 (+76.7%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
SLIGHTLY HIGH
Historical Trading Range
$8.05 -
$8.74
Company Quality Score
64/100
(BUY)
Volume Confirmation
HIGH
Confidence Score
60.5%
All Signals
- NEUTRAL: Mixed technical signals (55/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 76.7% below Wall St target ($15.20)
- BEARISH: Market expects 99.8% growth - appears too optimistic based on history
Trading Range Analysis
30-Day Trading Range
$8.05 -
$8.74
Current vs Trading Range
SLIGHTLY HIGH
Support & Resistance Levels
Support Level
$8.46
Resistance Level
$9.09
Current Trend
Strong Uptrend
Technical data as of
Jun 24, 2026
Fundamental Context
Forward P/E (Next Year Est.)
100.00
Wall Street Target
$15.20
(+76.7%)
Revenue Growth (YoY)
226.1%
Earnings Growth (YoY)
42.8%
Profit Margin
45.2%
Valuation Premium vs History
+99.8% premium
PE vs Historical
100.0 vs 12.5
STRETCHED
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+99.8%
(market-implied from PE analysis)
1-Year Target
$12.90
(+50%)
2-Year Target
$19.35
(+125%)
3-Year Target
$29.02
(+238%)
3-Yr Target (if PE normalizes)
(PE: 100→13)
PE COMPRESSION
$3.63
(-58%)
Significant PE compression expected
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 100.0, Growth: -82.8%)
$6.27
(+-27%)
Base:
(SPY PE: 21.8, Growth: -82.8%)
$1.37
(-84%)
Bear:
(PE: 12.5, Growth: -82.8%)
$0.78
(-91%)
📈
Valuation based on Current Earnings
Trailing PE: 4.06 | Current EPS (TTM): $2.17
Bull Case
$4.85
(-44%)
Analyst growth -50.0%, PE expands to 4.5
Base Case
$4.41
(-49%)
Market implied -50.0%, PE stable at 4.1
Bear Case
$6.00
(-30%)
Severe decline -20.0%, PE contracts to 3.5
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
Share & Embed Analysis
Last updated: June 24, 2026 4:44 PM ET
Data refreshes hourly during market hours. Next update: 5:44 PM
Data refreshes hourly during market hours. Next update: 5:44 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is CRMD showing a specific setup today?
Insider Activity (6 Months)
0
Buys
1
Sells
Net
INSIDERS SELLING
Recent Transactions
Alan W Dunton
SELL
20000 shares
2025-12-30
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
SRPT
Sarepta Therapeutics Inc |
STRONG BUY
26 analysts |
$22 | 53 HOLD |
|
NRIX
Nurix Therapeutics Inc |
STRONG BUY
18 analysts |
$31 | 61 BUY |
|
BNTX
BioNTech SE |
STRONG BUY
21 analysts |
$122 | 58 HOLD |
|
DNTH
Dianthus Therapeutics In… |
STRONG BUY
12 analysts |
$128 | 61 BUY |
|
DYN
Dyne Therapeutics Inc |
STRONG BUY
14 analysts |
$38 | 58 HOLD |
Advanced CRMD Option Strategies
Professional options setups generated by AI based on today's CRMD price and gamma walls.
